Literature DB >> 1374900

2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

J Balzarini1, M J Pérez-Pérez, A San-Félix, D Schols, C F Perno, A M Vandamme, M J Camarasa, E De Clercq.   

Abstract

A series of pyrimidine nucleoside analogues containing [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino- 1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-ribofuranose as the pentose were found to inhibit human immunodeficiency virus type 1 [HIV-1(IIIB)] replication at a concentration of 0.06-0.8 microM but were not cytotoxic at a 1000- to 10,000-fold higher concentration. These nucleoside derivatives were also effective against various other HIV-1 strains, including those resistant to 3'-azido-3'-deoxythymidine, but not against HIV-2, simian immunodeficiency virus, Moloney murine sarcoma virus, or other RNA or DNA viruses. They proved to be highly specific inhibitors of the RNA-dependent DNA polymerase function of the HIV-1 reverse transcriptase, showing no marked inhibition of the HIV-1 reverse transcriptase-associated DNA-dependent DNA polymerase activity, HIV-2 reverse transcriptase, DNA polymerase alpha, herpes simplex virus 1 DNA polymerase, or Thermus aquaticus DNA polymerase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374900      PMCID: PMC49088          DOI: 10.1073/pnas.89.10.4392

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.

Authors:  J Balzarini; L Naesens; J Slachmuylders; H Niphuis; I Rosenberg; A Holý; H Schellekens; E De Clercq
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

2.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.

Authors:  J Balzarini; C F Perno; D Schols; E De Clercq
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

4.  Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro.

Authors:  A Holý; I Votruba; A Merta; J Cerný; J Veselý; J Vlach; K Sedivá; I Rosenberg; M Otmar; H Hrebabecký
Journal:  Antiviral Res       Date:  1990-06       Impact factor: 5.970

5.  Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.

Authors:  P Huang; D Farquhar; W Plunkett
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

6.  An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.

Authors:  Z Debyser; R Pauwels; K Andries; J Desmyter; M Kukla; P A Janssen; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

Authors:  V J Merluzzi; K D Hargrave; M Labadia; K Grozinger; M Skoog; J C Wu; C K Shih; K Eckner; S Hattox; J Adams
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

8.  Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound.

Authors:  J Balzarini; Z Hao; P Herdewijn; D G Johns; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.

Authors:  M J Kukla; H J Breslin; R Pauwels; C L Fedde; M Miranda; M K Scott; R G Sherrill; A Raeymaekers; J Van Gelder; K Andries
Journal:  J Med Chem       Date:  1991-02       Impact factor: 7.446

10.  A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).

Authors:  H Tanaka; M Baba; H Hayakawa; T Sakamaki; T Miyasaka; M Ubasawa; H Takashima; K Sekiya; I Nitta; S Shigeta
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

View more
  20 in total

Review 1.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

Review 2.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

3.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; W G Tarpley; E De Clercq
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.

Authors:  Kalyan Das; Joseph D Bauman; Angela S Rim; Chhaya Dharia; Arthur D Clark; María-José Camarasa; Jan Balzarini; Eddy Arnold
Journal:  J Med Chem       Date:  2011-03-29       Impact factor: 7.446

6.  Peptides Mimicking the β7/β8 Loop of HIV-1 Reverse Transcriptase p51 as "Hotspot-Targeted" Dimerization Inhibitors.

Authors:  Pedro A Sánchez-Murcia; Sonia de Castro; Carlos García-Aparicio; M Angeles Jiménez; Angela Corona; Enzo Tramontano; Nicolas Sluis-Cremer; Luis Menéndez-Arias; Sonsoles Velázquez; Federico Gago; María-José Camarasa
Journal:  ACS Med Chem Lett       Date:  2020-01-24       Impact factor: 4.345

7.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 8.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

9.  Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Eugene L Asahchop; Maureen Oliveira; Matthew McCallum; Susan M Schader; Yingshan Han; Yudong Quan; Stefan G Sarafianos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

10.  Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase.

Authors:  E A Sudbeck; C Mao; R Vig; T K Venkatachalam; L Tuel-Ahlgren; F M Uckun
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.